Cited by 150Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease

Open access

Wang, Chang Yi, Wang, Pei‐Ning, Chiu, Ming‐Jang, Finstad, Connie L., Lin, Feng, Lynn, Shugene, Tai, Yuan‐Hung, De Fang, Xin, Zhao, Kesheng, Hung, Chung‐Ho, Tseng, Yiting, Peng, Wen‐Jiun, Wang, Jason, Yu, Chih‐Chieh, Kuo, Be‐Sheng, Frohna, Paul A.·2017·Alzheimer's & Dementia: Translational Research & Clinical Interventions

DOI 10.1016/j.trci.2017.03.005PMC PMC5651432

Open this paper in CoChat — free account Open PDF

Abstract

Introduction: A novel amyloid β (Aβ) synthetic peptide vaccine (UB‐311) has been evaluated in a first‐in‐human trial with patients of mild‐to‐moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase‐I clinical trial with supportive outcome that advances UB‐311 into an ongoing phase‐II trial. Methods: UB‐311 is constructed with two synthetic Aβ 1–14 –targeting peptides (B‐cell epitope), each linked to different helper T‐cell peptide epitopes (UBITh ® ) and formulated in a Th2‐biased delivery system. The hAPP751 transgenic mouse model was used to perform the proof‐of‐concept study. Baboons and macaques were used for preclinical safety, tolerability, and immunogenicity evaluation. Patients with mild‐to‐moderate Alzheimer's disease (AD) were immunized by intramuscular route with 3 doses of UB‐311 at weeks 0, 4, and 12, and monitored until week 48. Safety and immunogenicity were assessed per protocol, and preliminary efficacy was analyzed by Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog), Mini–Mental State Examination (MMSE), and Alzheimer's Disease Cooperative Study–Clinician's Global Impression of Change (ADCS‐CGIC). Results: UB‐311 covers a diverse genetic background and facilitates strong immune response with high responder rate. UB‐311 reduced the levels of Aβ 1–42 oligomers, protofibrils, and plaque load in hAPP751 transgenic mice. Safe and well‐tolerated UB‐311 generated considerable site‐specific (Aβ 1–10 ) antibodies across all animal species examined. In AD patients, UB‐311 induced a 100% responder rate; injection site swelling and agitation were the most common adverse events (4/19 each). A slower rate of increase in ADAS‐Cog from baseline to week 48 was observed in the subgroup of mild AD patients (MMSE ≥ 20) compared with the moderate AD subgroup, suggesting that UB‐311 may have a potential of cognition improvement in patients with early stage of Alzheimer's dementia. Discussion: The UBITh ® platform can generate a high‐precision molecular vaccine with high responder rate, strong on‐target immunogenicity, and a potential of cognition improvement, which support UB‐311 for active immunotherapy in early‐to‐mild AD patients currently enrolled in a phase‐II trial ( NCT02551809 ).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.trci.2017.03.005

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102

Flagged first, then by citations

Show all 52 references

Sorted by citations

Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 300
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Cummings, J. L. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 266
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Membrane Active Peptides and Their Biophysical Characterization
Avcı, F. G., Akbulut, B. S., & Özkırımlı, E. (2018) · Biomolecules · doi:10.3390/biom8030077 · Cited by 215
Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update
Yadollahikhales, G., & Rojas, J. C. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01405-0 · Cited by 165
Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases
Baig, M. H., Ahmad, K., Saeed, M., Alharbi, A. M., Barreto, G. E., Ashraf, G. M., & Choi, I. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.025 · Cited by 154
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 144
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125
Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research
Dennison, J. L., Ricciardi, N. R., Lohse, I., Volmar, C., & Wahlestedt, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201014 · Cited by 107
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Development of therapeutic vaccines for the treatment of diseases
Tian, Y., Hu, D., Li, Y., & Li, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00098-9 · Cited by 89
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 69
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
Yu, H. J., Dickson, S. P., Wang, P., Chiu, M., Huang, C., Chang, C., Liu, H., Hendrix, S. B., Dodart, J., Verma, A. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104665 · Cited by 72
Self-citation
Targeting aging and age-related diseases with vaccines
Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66
The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer’s Disease
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 64
Self-citation
The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 58
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
Yu, H. J., Thijssen, E., van Brummelen, E. M. J., van der Plas, J. L., Radanović, I., Moerland, M., Hsieh, E., Groeneveld, G. J., & Dodart, J. (2022) · Movement Disorders · doi:10.1002/mds.29016 · Cited by 66
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 59
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 60
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Nimmo, J., Verma, A. K., Dodart, J., Wang, C. Y., Savistchenko, J., Melki, R., Carare, R. O., & Nicoll, J. A. R. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00727-x · Cited by 48
Self-citation
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 48
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46
Alzheimer’s Disease: Drug Discovery
Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 49
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40
Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 44
Molecular simulations of amyloid beta assemblies
Grasso, G., & Danani, A. (2020) · Advances in Physics X · doi:10.1080/23746149.2020.1770627 · Cited by 40
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding
Liang, C., Savinov, S. N., Fejzo, J., Eyles, S. J., & Chen, J. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00599 · Cited by 41
Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
Davtyan, H., Hovakimyan, A., Kiani Shabestari, S., Antonyan, T., Coburn, M. A., Zagorski, K., Chailyan, G., Petrushina, I., Svystun, O., Danhash, E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0556-2 · Cited by 37
Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 45
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 35
Rationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 35
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Nimmo, J., Smith, H., Wang, C. Y., Teeling, J. L., Nicoll, J. A. R., Verma, A. K., Dodart, J., Liu, Z., Feng, L., & Carare, R. O. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02381-5 · Cited by 32
Self-citation
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
Wang, S., Wang, C. Y., Kuo, H.-K., Peng, W., Huang, J.-H., Kuo, B.-S., Feng, L., Liu, Y.-J., Liu, Z., Wu, H.-T., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2140608 · Cited by 33
Self-citation
Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia
Decourt, B., Noorda, K., Noorda, K. J., Shi, J., & Sabbagh, M. N. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265626 · Cited by 33
Promising Results from Alzheimer’s Disease Passive Immunotherapy Support the Development of a Preventive Vaccine
Marciani, D. J. (2019) · Research · doi:10.34133/2019/5341375 · Cited by 33
Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42
Song, C., Zhang, T., & Zhang, Y. (2022) · Molecules · doi:10.3390/molecules27196751 · Cited by 33
Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 32
Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy
Kelly, L., Brown, C., Michalik, D., Hawkes, C. A., Aldea, R., Agarwal, N., Salib, R. J., Alzetani, A., Ethell, D. W., Counts, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13512 · Cited by 31
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Vroom, M. M., Lu, H., Lewis, M., Thibodeaux, B. A., Brooks, J. K., Longo, M. S., Ramos, M. M., Sahni, J., Wiggins, J., Boyd, J. D., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100497 · Cited by 29
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 34
Self-citation
The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer’s Disease
Zhuang, X., Jie, L., Song, Y., Ban, R., Zhao, X., Xia, Z., Wang, Z., & Zhang, G. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08815-z · Cited by 33
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Changes in the brain transcriptome after DNA Aβ42 trimer immunization in a 3xTg-AD mouse model
Lambracht‐Washington, D., Fu, M., Hynan, L. S., & Rosenberg, R. N. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105221 · Cited by 27
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
Henrı́quez, G., & Narayan, M. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00048 · Cited by 27
Alzheimer Disease Clinical Trials Targeting Amyloid
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 27
Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
Lin, S.-Y., Lin, K., Lin, P.-C., Huang, C.-C., Chang, C., Lee, Y., Hsiao, I., Yen, T., Huang, W.-S., Yang, B., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0566-0 · Cited by 26
Self-citation
Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
Vassilakopoulou, V., Karachaliou, C., Evangelou, A., Zikos, C. C., & Livaniou, E. (2021) · Vaccines · doi:10.3390/vaccines9111278 · Cited by 27
Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 25
Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
Barrera-Ocampo, A. A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.034 · Cited by 30
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Vissers, M. F. J. M., Heuberger, J. A. A. C., & Groeneveld, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041615 · Cited by 24
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 28
Capillary electrophoresis in the analysis of therapeutic peptides—A review
Štefánik, O., Majerová, P., Kováč, A., Mikuš, P., & Piešťanský, J. (2023) · Electrophoresis · doi:10.1002/elps.202300141 · Cited by 25
The Impact of Natural Compounds on S-Shaped Aβ42 Fibril: From Molecular Docking to Biophysical Characterization
Muscat, S., Pallante, L., Stojceski, F., Danani, A., Grasso, G., & Deriu, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062017 · Cited by 26
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Park, K. W. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00848-3 · Cited by 25
Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches
Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 27
Nanoparticles for immunotherapy
Anfray, C., Mainini, F., & Andón, F. T. (2020) · Frontiers of nanoscience · doi:10.1016/b978-0-08-102828-5.00011-5 · Cited by 21
Passive Immunotherapies Targeting Amyloid-β in Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 20
Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 21
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 19
A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an AAV hACE2 Mouse Model and non-human primatesPreprint
Guirakhoo, F., Kuo, L., Peng, J., Huang, J.-H., Kuo, B.-S., Lin, F., Liu, Y.-J., Liu, Z., Wu, G., Ding, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.30.399154 · Cited by 16
Self-citation
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 15
An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β1
Song, G., Yang, H., Shen, N., Pham, P., Brown, B., Lin, X., Hong, Y., Paul, S., Cai, J., Li, X., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200413 · Cited by 16
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 15
Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches
Atoki, A. V., Aja, P. M., Ondari, E. N., & Shinkafi, T. S. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2243050 · Cited by 20
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders
Palumbo, M. L., Moroni, A. D., Quiroga, S., Castro, M. M., Burgueño, A. L., & Genaro, A. M. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.795 · Cited by 12
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 13
Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice
Zhang, H., Zhu, K., Meng, Y., Ding, L., Wang, J.-C., Yin, W., Yan, Y., & Cao, Y. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.07.019 · Cited by 13
Self-citation
Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
Weninger, S. C., Sperling, B., Alexander, R., Ivarsson, M., Menzies, F. M., Powchik, P., Weber, C. J., Altar, C. A., Crystal, R. G., Haggarty, S. J., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12090 · Cited by 13
Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease
Xu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14238 · Cited by 11
Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 14
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16
Moxifloxacin Disrupts and Attenuates Aβ42 Fibril and Oligomer Formation: Plausibly Repositioning an Antibiotic as Therapeutic against Alzheimer’s Disease
Khan, A. N., Nabi, F., Ajmal, M. R., Ali, S. M., Almutairi, F. M., Alalawy, A. I., & Khan, R. H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00371 · Cited by 12
Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes
Kaushal, N., Jain, S., & Baranwal, M. (2022) · Journal of Molecular Recognition · doi:10.1002/jmr.2961 · Cited by 11
Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review
Mahdiabadi, S., Momtazmanesh, S., Perry, G. L., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0092 · Cited by 13
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11
Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 10
Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Vroom, M. M., & Dodart, J. (2024) · Vaccines · doi:10.3390/vaccines12090973 · Cited by 10
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 11
A brief history of antibody-based therapy
Alpaugh, M., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104504 · Cited by 10

Authors: Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., Tseng, Y., Peng, W., Wang, J., Yu, C., Kuo, B., & Frohna, P. A.
Affiliations: United Biomedical (United States) (US)
Taipei Veterans General Hospital (TW)
National Taiwan University Hospital (TW)
United Biomedical Inc. Asia (UBI‐Asia) Hsinchu Taiwan
United Biomedical, Inc. (UBI) Hauppauge NY USA
United Neuroscience, Inc. (UNS) Hsinchu Taiwan
Corresponding author: Wang, Chang Yi
ORCID: Wang, Pei‐Ning
Chiu, Ming‐Jang
Wang, Jason
Frohna, Paul A.
Venue: Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher: Wiley
Published: 2017-04-14
Volume: 3
Issue: 2
Pages: 262-272
ISSN: 2352-8737 (ISSN-L)
DOI: 10.1016/j.trci.2017.03.005
PMC: PMC5651432
OpenAlex: W2605942834
Cited by: 150
References: 52
Citations by year: 2026: 13 · 2025: 17 · 2024: 19 · 2023: 19 · 2022: 20 · 2021: 18 · 2020: 20 · 2019: 16 · 2018: 7
FWCI: 8.69
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: United Biomedical, Inc., Hauppauge, New York
United Biomedical, Inc., Asia, Taiwan
Ministry of Economic Affairs Grant, Taiwan
UBITh AD Immunotherapeutic Vaccine [UB-311] (98-EC-17-A-20-1-0014)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, mild to moderate Alzheimer's disease, B-cell epitopes, helper T cell epitopes, immunogenicity, vaccine safety, amyloid plaques, baboons, macaque

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks